Lentinan inhibits colorectal cancer stemness by binding CD133 and suppressing the CD133/p85/p-AKT signaling axis
Open Access
- 10 December 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1725716
Abstract
Background: Colorectal cancer (CRC) ranks third in the global cancer incidence rate worldwide. Cancer stem cells (CSCs) are key drivers of CRC recurrence, metastasis, and therapy resistance, while therapies against them remain limited. Lentinan is widely recognized for its strong immune-enhancing and broad-spectrum directly antitumor activities, however, whether it has potential for cancer stemness remains unknown. Methods: The CRC cell lines HCT116 and SW620 were selected for pharmacodynamic investigation. Furthermore, tumor sphere formation and limiting dilution assays were used to assess the impact of SLNT on stemness of CRC. Using cell sorting alongside cluster of differentiation 133 (CD133) knockdown and overexpression experiments, the key molecular targets of SLNT in exerting anti-CRC effects were identified. To further elucidate the underlying molecular mechanism, we performed localized surface plasmon resonance (LSPR), cellular thermal shift assay (CETSA), and molecular docking simulations. Additionally, western blot analysis was conducted to validate the key signaling molecules involved. Results: Our results demonstrated that lentinan significantly suppressed the proliferation and stemness of CRC cell lines HCT116 and SW620. We identified CD133 as a critical functional target and confirmed a direct binding interaction between lentinan and CD133. Finally, we revealed that lentinan suppresses stemness by inhibiting the CD133/ phosphatidylinositol 3-kinase 85 kDa regulatory subunit (p85)/ phosphorylated AKT serine/threonine kinase (p-AKT) signaling axis in CRC. Conclusion: Our findings not only shed new light on the anti-tumor mechanism of lentinan, highlighting the scientific potential of natural polysaccharides in cancer treatment, but also offers new options for the clinical drug therapy of CRC.Keywords
This publication has 83 references indexed in Scilit:
- PAX2 induces endometrial cancer by inhibiting mitochondrial function via the CD133—AKT1 pathwayMolecular and Cellular Biochemistry, 2025
- Evolving landscape of colorectal cancer: Global and regional burden, risk factor dynamics, and future scenarios (the Global Burden of Disease 1990–2050)Ageing Research Reviews, 2025
- Functional Roles of CD133: More than Stemness Associated Factor Regulated by the MicroenvironmentStem Cell Reviews and Reports, 2023
- LXR inhibitor SR9243-loaded immunoliposomes modulate lipid metabolism and stemness in colorectal cancer cellsMedical Oncology, 2023
- Extraction, purification, bioactivities and prospect of lentinan: A reviewBiocatalysis and Agricultural Biotechnology, 2021
- The binding of LDN193189 to CD133 C-terminus suppresses the tumorigenesis and immune escape of liver tumor-initiating cellsCancer Letters, 2021
- CD133 prevents colon cancer cell death induced by serum deprivation through activation of Akt‐mediated protein synthesis and inhibition of apoptosisFEBS Open Bio, 2021
- The structure–activity relationships of natural glucansPhytotherapy Research, 2020
- CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinomaCancer Letters, 2017
- Dose Dependency of the Kinetics of Dextrans in Rats: Effects of Molecular WeightJournal of Pharmaceutical Sciences, 1995